Oxford Biodynamics Share Discussion Threads

[smithie6] 26/10/2023 15:49

Boysie72

..idiot imo

[intoodeep] 26/10/2023 15:49

Your boring everyone now, you won't shup up because your type never do, it's pathetic.

[smithie6] 26/10/2023 15:46

Blah blah blah.

OBD has not created a yes/no test for prostate cancer. Full stop.

If it had its share price would be much higher.

....if potential shareholders need to first have a degree in human pharma stuff & read the OBD test reports & understand words like "epigenetic biomarkers"

Then the number of potential shareholders in the UK where OBD is listed is quite small.

I'm not interested to devote the time to learn about all this medical jargon such as "epigenetic biomarkers". I note the words genetic & surveillance of people that have been tested.

If OBD come up with a yes/no test for prostate cancer then I would be interested to again buy/hold some shares.

-----

Usual low quality of posts on ADVFN.
'you don't like the shares so I'm going to slag you off'

Infers that some posters are not very shrewd/wise.

[boysie72] 26/10/2023 15:20

Smithie6 is another poster who has been filtered for ages, cannot remember what stock, but I usually filter those that are trolling. But you have identified the agenda of this person swiftly, well done. Trolls are lazy, their lack of effort in portraying intellect or actually having knowledge makes it easy to identify them and filter them promptly. Add their posting history in to the mix and it is case closed for me.If the USA or BUPA start questioning the use and need for the product, then I will listen to them in an instance.

[theclangers] 26/10/2023 15:16

I agree with that sunshine, I can see lots of potential in the CiRT test as well, nothing out there comes close to it's accuracy, It's now, a new tool that can be used in the fight against Cancer.

[givmesunshine] 26/10/2023 15:02

Its important to look at the negatives and not get carried away - but the last 2 rns's are just as important, actually even more than the first one that sent it on its way.. Cirt news is huge on its own. and Unique Medicare code in that timeframe is unheard of

[intoodeep] 26/10/2023 14:59

GMS, Clearly Smithie has an agenda but he's totally wrong in every aspect.

[givmesunshine] 26/10/2023 14:58

250% in 4 weeks ? CIRT noe being offered to all eligible paitents by Bupa(OXB getting $200-$2500 A pop in the US), Unique Medicare code for PSE GRANTED and recieved in weeks (often wait years) and your not keen- Something is pathetic , not sure its the test though :)

[intoodeep] 26/10/2023 14:57

Smithie I have no idea why you are being so obtuse about this, it's very, very clear.

The PSE test is designed to run alongside a standard PSA test, and combines the PSA score with five proprietary epigenetic biomarkers to predict, with 94% accuracy, the presence (or absence) of prostate cancer.

You can play semantics all day long if you want but it's nothing more than FUD imo.

[smithie6] 26/10/2023 14:54

I made a nice profit from the initial rise & sold.

Since then I see no reason at all to buy back in since it appears that OBD have NOT produced a yes/no test for prostate cancer. And maybe there is an element of hot air & a risk the share price will just slide back down as the initial excitement gets cold.

[theclangers] 26/10/2023 14:41

smithie, it's not black or white, one or the other, It's more a mater of opinion, how many new (more accurate) PSE test are going to be used in conjunction with the (old) existing PSA test, variables are involved too, like price of the new test, the availability. Investors need to draw their own conclusions. If it was nailed on already, all test are going to be done with the new PSE add on, then you would be looking at a very different M-cap of 69M more like multi billions

[smithie6] 26/10/2023 14:39

....completely unclear imo

-----

'likelihood' & 'on-going surveillance'

Sounds a bit pathetic to me.

Surely what the world needs/wants is 1 test that gives a result for whether the person has prostate cancer, yes or no.

People want a yes/no result.
People do NOT want to have 2 different tests and then be told that they need 'on-going surveillance' !!
& have doubt about whether they have prostate cancer or not.

2 different tests & 'likelihood' & 'surveillance'
....a cynic might say that that sounds pretty useless & is a long way away from what the health market wants/needs.

& is why the shares have NOT rocketted.

[intoodeep] 26/10/2023 14:30

Is that reasonable enough for you smithie?

[intoodeep] 26/10/2023 14:29

The PSE test is designed to run alongside a standard PSA test, and combines the PSA score with five proprietary epigenetic biomarkers to predict, with 94% accuracy, the presence (or absence) of prostate cancer.2 Those with a PSE result of low likelihood of cancer can be placed on active surveillance and retested later without being referred for an invasive and often destructive biopsy. A high likelihood result would necessitate referral to a Urologist for further investigation.

[cyberbub] 26/10/2023 14:28

Sunshine your post 1389, 500 CIRT tests per month across the USA and now BUPA is a low target IMO, the way they were rising it wouldn't surprise me if we were there by Xmas. Hopefully we'll get an update soon?

[cyberbub] 26/10/2023 14:14

Smithie you've not been reading enough. OBD's test (PSE) is used *together* with the existing test (PSA). But you need the former to achieve the 94% accuracy. It's not difficult to understand IMO

[smithie6] 26/10/2023 13:51

Boysie72

In simple terms.....does the OBD prostate cancer test (94% accurate ??) replace the previous existing test (~50% accurate) ?

If not can you explain why not ?!

I understand that the OBD test does NOT replace the less accurate previous test.
I have not seen a simple/understandable explanation for that.
If the previous test is not replaced by the OBD test then the shares are less exciting imo.

[boysie72] 26/10/2023 12:16

Here is the link to the post on X. This paper was published Jan 23 and it explains and brings transparency to how OBD have reached the advances and collaborations they have today. The average human life expectancy has increased over the centuries due to medical science achievements, this is now one of them..https://x.com/oxbiodynamics/status/1717211664779456861?s=46

[boysie72] 26/10/2023 11:59

For those interested in facts and reality, here is a link to the paper in the journal. It is quite a read and content will need further research just to understand the content!For me, this is the most important reference point for my investment in this company. Enjoy reading. .https://www.mdpi.com/2072-6694/15/3/821

[boysie72] 26/10/2023 09:30

NYBoy goes round numerous boards bashing stocks he does not hold, so a troll with an agenda. Posting history always reveals truth. I have had this person on filter for ages, but from the responses of unfiltered posters I would say that your indicator is the USA and BUPA, not a bulk standard ADVFN troll with zero medical sector knowledge around the product in question. An opinion is not fact, the facts come from the company and the sector. For instance, OBD posted on X about one of their papers published within a cancer journal. Huge amount of information to be had from that post, and additional insight around response from peers within this sector. Easy research for those that can be bothered. Just to clarify, NYBoy was not not mentioned in the journal nor identified as a peer. GL genuine holders.

[givmesunshine] 26/10/2023 08:21

The importamce of getting the unique medicare code cannot underestimated, I think the starting 6 months may take a while to get moving - The key is to spread awareness that the test is avaiable to US paitents at that they can now request it.

However - Cirt is a biggie. At last count only 97 tests a month, at approx %2200 at test, with Gross Margins looking to be 70% min and with over 100% growth on tests completed in the previous 2 months. Even at thi cornershop level thats about $2,600,000 rev on a annual basis, 500+ tests a month and OBD stops being a cash burner. And with Bupa offering it to all eligible patients.

Unless there is some elaborate fraud - this is one the most exciting growth potential AIM ive seen in decades

[cyberbub] 26/10/2023 08:15

The 2 x 25k trades gone through look like a rollover but I can confirm that they were buys :-)

[cyberbub] 26/10/2023 08:11

Don't forget that a bigger fish could fancy a meal here as well. With all the potential (starting to become hard reality), a US pharma company will be laughing their socks off at a sub-$100M valuation. It would be 3-4x that today with a US listing IMO. There is over a decade of research and investment has gone into OBD.

[theclangers] 26/10/2023 00:02

The NHS performs 5 million PSA tests a year, quite small compared to the 25 million in the US. The big bucks are going to be made from across the pond.

[ny boy] 25/10/2023 22:40

Well I like the product but not the price point, let’s hope it becomes much cheaper as it becomes more scalable. Certainly anything to do without having a biopsy is a game changer. I will take a position soon on this retrace, it a large position.